NYSE:BDX - Becton Dickinson and Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$251.61 -1.20 (-0.47 %)
(As of 08/21/2018 04:00 PM ET)
Previous Close$254.00
Today's Range$251.37 - $254.92
52-Week Range$191.53 - $254.35
Volume48,932 shs
Average Volume947,837 shs
Market Capitalization$67.73 billion
P/E Ratio26.82
Dividend Yield1.19%
Becton Dickinson and logoBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio0.95
Current Ratio1.23
Quick Ratio0.81


Trailing P/E Ratio26.82
Forward P/E Ratio22.85
P/E Growth1.72

Sales & Book Value

Annual Sales$12.09 billion
Price / Sales5.57
Cash Flow$14.0173 per share
Price / Cash17.95
Book Value$56.89 per share
Price / Book4.42


EPS (Most Recent Fiscal Year)$9.48
Net Income$1.10 billion
Net Margins4.73%
Return on Equity14.16%
Return on Assets5.39%


Outstanding Shares267,560,000
Market Cap$67.73 billion

Becton Dickinson and (NYSE:BDX) Frequently Asked Questions

What is Becton Dickinson and's stock symbol?

Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and?

Becton Dickinson and announced a quarterly dividend on Tuesday, July 24th. Investors of record on Friday, September 7th will be paid a dividend of $0.75 per share on Friday, September 28th. This represents a $3.00 annualized dividend and a yield of 1.19%. The ex-dividend date is Thursday, September 6th. View Becton Dickinson and's Dividend History.

How were Becton Dickinson and's earnings last quarter?

Becton Dickinson and Co (NYSE:BDX) issued its earnings results on Thursday, August, 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $2.86 by $0.05. The medical instruments supplier had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The business's revenue was up 41.0% on a year-over-year basis. During the same period last year, the business earned $2.46 EPS. View Becton Dickinson and's Earnings History.

When is Becton Dickinson and's next earnings date?

Becton Dickinson and is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Becton Dickinson and.

What guidance has Becton Dickinson and issued on next quarter's earnings?

Becton Dickinson and updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided EPS guidance of $10.95-11.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.98.

What price target have analysts set for BDX?

13 Wall Street analysts have issued twelve-month target prices for Becton Dickinson and's shares. Their forecasts range from $175.00 to $283.00. On average, they anticipate Becton Dickinson and's stock price to reach $246.8462 in the next twelve months. This suggests that the stock has a possible downside of 2.0%. View Analyst Price Targets for Becton Dickinson and.

What is the consensus analysts' recommendation for Becton Dickinson and?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton Dickinson and in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Becton Dickinson and.

Who are some of Becton Dickinson and's key competitors?

Who are Becton Dickinson and's key executives?

Becton Dickinson and's management team includes the folowing people:
  • Mr. Vincent A. Forlenza, Chairman & CEO (Age 65)
  • Mr. Thomas E. Polen Jr., Pres (Age 45)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 61)
  • Mr. Alexandre Conroy, Pres of Worldwide Medication & Procedural Solutions (Age 55)
  • Mr. James W. Borzi, Exec. VP of Global Operations & Chief Supply Chain Officer (Age 55)

Has Becton Dickinson and been receiving favorable news coverage?

News stories about BDX stock have trended somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Becton Dickinson and earned a media and rumor sentiment score of 0.15 on Accern's scale. They also assigned media coverage about the medical instruments supplier an impact score of 41.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Becton Dickinson and.

Who are Becton Dickinson and's major shareholders?

Becton Dickinson and's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.02%), FMR LLC (6.35%), Wells Fargo & Company MN (1.32%), Putnam Investments LLC (1.31%), Fiera Capital Corp (1.05%) and Bank of America Corp DE (1.03%). Company insiders that own Becton Dickinson and stock include Alexandre Conroy, David F Melcher, Ellen R Strahlman, Gary M Cohen, James W Borzi, Jeffrey S Sherman, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Institutional Ownership Trends for Becton Dickinson and.

Which institutional investors are selling Becton Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Janus Henderson Group PLC, Jensen Investment Management Inc., Los Angeles Capital Management & Equity Research Inc., Russell Investments Group Ltd., BlackRock Inc., Dividend Assets Capital LLC and Natixis. Company insiders that have sold Becton Dickinson and company stock in the last year include Alexandre Conroy, Gary M Cohen, James W Borzi, John E Gallagher, Linda M Tharby, Nabil Shabshab, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Insider Buying and Selling for Becton Dickinson and.

Which institutional investors are buying Becton Dickinson and stock?

BDX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Charles Schwab Investment Advisory Inc., Vontobel Asset Management Inc., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Findlay Park Partners LLP, Cornerstone Wealth Management LLC, Sei Investments Co. and Point72 Asset Management L.P.. View Insider Buying and Selling for Becton Dickinson and.

How do I buy shares of Becton Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Becton Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $251.97.

How big of a company is Becton Dickinson and?

Becton Dickinson and has a market capitalization of $67.73 billion and generates $12.09 billion in revenue each year. The medical instruments supplier earns $1.10 billion in net income (profit) each year or $9.48 on an earnings per share basis. Becton Dickinson and employs 41,933 workers across the globe.

How can I contact Becton Dickinson and?

Becton Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.

MarketBeat Community Rating for Becton Dickinson and (NYSE BDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  475 (Vote Underperform)
Total Votes:  867
MarketBeat's community ratings are surveys of what our community members think about Becton Dickinson and and other stocks. Vote "Outperform" if you believe BDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel